30 June 2009: End of Trial
UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.
Read more about this topic: CDP323
Famous quotes containing the words june and/or trial:
“Wine and cheese are ageless companions, like aspirin and aches, or June and moon, or good people and noble ventures ...”
—M.F.K. Fisher (1908–1992)
“The trial by market everything must come to.”
—Robert Frost (1874–1963)